Want to see AQST full AI Analyst Report?
Total Valuation
Aquestive Therapeutics has a market cap or net worth of $564.17M. The enterprise value is $570.57.
Market Cap$564.17M
Enterprise Value$570.57
Share Statistics
Aquestive Therapeutics has 125,511,650 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding125,511,650
Owned by Insiders2.25%
Owned by Institutions23.67%
Financial Efficiency
Aquestive Therapeutics’s return on equity (ROE) is 2.49 and return on invested capital (ROIC) is -55.97%.
Return on Equity (ROE)2.49
Return on Assets (ROA)-0.52
Return on Invested Capital (ROIC)-55.97%
Return on Capital Employed (ROCE)-0.62
Revenue Per Employee303.03K
Profits Per Employee-569.96K
Employee Count147
Asset Turnover0.28
Inventory Turnover2.78
Valuation Ratios
The current PE Ratio of Aquestive Therapeutics is ―. Aquestive Therapeutics’s PEG ratio is -0.17.
PE Ratio―
PS Ratio17.69
PB Ratio-23.41
Price to Fair Value-23.41
Price to FCF-14.87
Price to Operating Cash Flow-12.84
PEG Ratio-0.17
Income Statement
In the last 12 months, Aquestive Therapeutics had revenue of 44.55M and earned -83.78M in profits. Earnings per share was -0.76.
Revenue44.55M
Gross Profit27.39M
Operating Income-69.65M
Pretax Income-83.78M
Net Income-83.78M
EBITDA-66.13M
Earnings Per Share (EPS)-0.76
Cash Flow
In the last 12 months, operating cash flow was -45.37M and capital expenditures -584.00K, giving a free cash flow of -45.95M billion.
Operating Cash Flow-45.37M
Free Cash Flow-45.95M
Free Cash Flow per Share-0.37
Dividends & Yields
Aquestive Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.92
52-Week Price Change20.73%
50-Day Moving Average4.17
200-Day Moving Average4.49
Relative Strength Index (RSI)67.51
Average Volume (3m)2.09M
Important Dates
Aquestive Therapeutics upcoming earnings date is Nov 9, 2026, After Close (Confirmed).
Last Earnings DateAug 11, 2026
Next Earnings DateNov 9, 2026
Ex-Dividend Date―
Financial Position
Aquestive Therapeutics as a current ratio of 3.14, with Debt / Equity ratio of -104.26%
Current Ratio3.14
Quick Ratio3.01
Debt to Market Cap0.16
Net Debt to EBITDA-0.16
Interest Coverage Ratio-4.07
Taxes
In the past 12 months, Aquestive Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aquestive Therapeutics EV to EBITDA ratio is -12.07, with an EV/FCF ratio of -15.06.
EV to Sales17.92
EV to EBITDA-12.07
EV to Free Cash Flow-15.06
EV to Operating Cash Flow-15.22
Balance Sheet
Aquestive Therapeutics has $98.49M in cash and marketable securities with $59.00M in debt, giving a net cash position of $39.49M billion.
Cash & Marketable Securities$98.49M
Total Debt$59.00M
Net Cash$39.49M
Net Cash Per Share$0.31
Tangible Book Value Per Share-$0.28
Margins
Gross margin is 67.04%, with operating margin of -156.36%, and net profit margin of -188.09%.
Gross Margin67.04%
Operating Margin-156.36%
Pretax Margin-188.09%
Net Profit Margin-188.09%
EBITDA Margin-148.45%
EBIT Margin-149.70%
Analyst Forecast
The average price target for Aquestive Therapeutics is $8.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$8.75
Price Target Upside137.77% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast22.56%
EPS Growth Forecast5.86%